Canada Spends Logo

Explore our Budget 2026 analysis

Contribution: Industrial Research Assistance Program

Light Matter Interaction Inc.

$242,500.00

Precision Drug Delivery via Laser-Activated Microfluidic Fibers

FY 2025-26 · 2025-09-01

Summary
This project aims to develop and validate a novel platform for laser-assisted targeted drug delivery using LMI's proprietary picosecond mid-infrared laser technology. This technology enables precise ablation of tissues and when coupled to a microfluidic drug channel, the optic probe can deliver localized therapeutics with high resolution and minimal invasiveness. LMI holds foundational IP specific to this application covering fiberoptic laser-drug delivery systems in addition to the original core IP portfolio covering the unique laser tissue interaction. The platform will be validated in, phantom tissue, ex vivo and animal models, focusing on applications in high-value organ systems: prostate, brain, lung, and pancreas.
Program
Industrial Research Assistance Program
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
808272470
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions

Amendments

Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.

AmendmentDateFiscal YearTotal
02025-09-012025-26$242,500.00
22025-09-012025-26$242,500.00

As published

Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 91 jours.
Agreement End Date
2026-11-30
Agreement Number
1034613
Agreement Start Date
2025-09-01
Agreement Title
Precision Drug Delivery via Laser-Activated Microfluidic Fibers
Agreement Title (French)
Délivrance précise de médicaments au moyen de fibres microfluidiques activées par laser
Agreement Type
Contribution
Agreement Value
$242,500.00
Amendment Date
2026-08-06
Amendment Number
2
Coverage
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity. | Les projets du Programme d'aide à la recherche industrielle favorisent la création de richesse au Canada grâce à l'innovation technologique et renforcent l'écosystème canadien de l'innovation en créant de nouvelles capacités industrielles.
Description
This project aims to develop and validate a novel platform for laser-assisted targeted drug delivery using LMI's proprietary picosecond mid-infrared laser technology. This technology enables precise ablation of tissues and when coupled to a microfluidic drug channel, the optic probe can deliver localized therapeutics with high resolution and minimal invasiveness. LMI holds foundational IP specific to this application covering fiberoptic laser-drug delivery systems in addition to the original core IP portfolio covering the unique laser tissue interaction. The platform will be validated in, phantom tissue, ex vivo and animal models, focusing on applications in high-value organ systems: prostate, brain, lung, and pancreas.
Description (French)
Ce projet vise à développer et à valider une nouvelle plateforme pour l’administration ciblée de médicaments assistée par laser en utilisant la technologie propriétaire du laser picoseconde dans l’infrarouge moyen de LMI. Cette technologie permet une ablation précise des tissus et, lorsqu’elle est couplée à un canal de médicaments microfluidique, la sonde optique peut délivrer des médicaments localisés avec une haute résolution et une invasivité minimale. LMI détient une propriété intellectuelle fondamentale spécifique à cette application, couvrant les systèmes d’administration de médicaments par laser à fibre optique, en plus du portefeuille original de propriété intellectuelle de base couvrant l’interaction unique entre le laser et les tissus. La plateforme sera validée sur des tissus fantômes, ex vivo et sur des modèles animaux, en se concentrant sur des applications dans des systèmes organiques de grande valeur : prostate, cerveau, poumon et pancréas.
Expected Results
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Expected Results (French)
Les résultats attendus du Programme d’aide à la recherche industrielle du CNRC sont axés sur la croissance des petites et moyennes entreprises (PME) grâce à l’innovation et à la création de richesse pour le Canada.
Federal Riding
Taiaiako’n—Parkdale—High Park
Federal Riding (French)
Taiaiako’n—Parkdale—High Park
Federal Riding Number
35105
NAICS Code
339990
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program
Program Name (French)
Programme d’aide à la recherche industrielle
Program Purpose
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Program Purpose (French)
Les contributions versées aux entreprises en vertu du Programme d’aide à la recherche industrielle ont pour objectif d’apporter un soutien aux petites et moyennes entreprises (PME) afin qu’elles puissent approfondir leurs connaissances en matière d’innovation et renforcer leur capacité d’innovation, de croissance et de création de richesse pour le Canada.
Recipient Business Number
808272470
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Light Matter Interaction Inc.
Recipient Postal Code
M6N 3C5
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2025-2026-Q2-1034613